[HTML][HTML] Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

J Lam, CA Nelson, FP Ross… - The Journal of …, 2001 - Am Soc Clin Investig
J Lam, CA Nelson, FP Ross, SL Teitelbaum, DH Fremont
The Journal of clinical investigation, 2001Am Soc Clin Investig
RANK, the receptor activator of NF-κB, and its ligand RANKL (initially termed TRANCE, also
termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the
development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While
TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs
associate with high specificity. Given the low level of amino acid conservation among
members of the TNF superfamily, the means by which these molecules achieve specificity …
RANK, the receptor activator of NF-κB, and its ligand RANKL (initially termed TRANCE, also termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs associate with high specificity. Given the low level of amino acid conservation among members of the TNF superfamily, the means by which these molecules achieve specificity cannot be completely understood without knowledge of their three-dimensional structures. To determine the elements of RANKL that mediate RANK activation, we have crystallized the ectodomain of murine RANKL and solved its structure to a resolution of 2.6 Å. RANKL self-associates as a homotrimer with four unique surface loops that distinguish it from other TNF family cytokines. Mutagenesis of selected residues in these loops significantly modulates RANK activation, as evidenced by in vitro osteoclastogenesis, thereby establishing their necessity in mediating the biological activities of RANKL. Such structural determinants of RANKL-RANK specificity may be of relevance in the pharmacologic design of compounds to ameliorate osteopenic disorders of bone.
The Journal of Clinical Investigation